Search 

Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies

CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications

immuno-oncology

inflammatory diseases

inflammatory autoimmune 

big data

biomarker

Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.

The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.  

CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials. 

DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.

We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.

DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.

Dolopharm is a drug development company from Charité, Berlin, with a focus on GPCR-targeted therapies. Our first pipeline candidate NFEPP for the treatment of severe acute and chronic pain has shown impressive performance in several pre-clinical trial models. In contrast to standard medications, such as opioids, NFEPP avoids drug addiction, respiratory depression, constipation and other known side effects thus representing a potential breakthrough medication for many pain related indications. 

Drug Development

New Drugs

Pain therapy

Start-up seeking for initial financing

We are currently looking for investors to finance our clinical phase I studies in post-operative pain treatment after knee surgery. So, feel free to talk to us and find out, how to join this outstanding investment opportunity.

Since more than 450mio people have a bad mental being affecting their capacity ‘’to work and to love’’, our next step is to apply our technology to a life coaching app combining psychological and genetic data analysis coupled with artificial intelligence. 

At your fingertip, you will have access to our existing network of coaches and specialists who can help you improve your overall wellbeing by understanding the real you.

DNA, PSYCHOLOGY, NATURE, NURTURE, COACHING, BIOTECH, GENETIC TEST, ASSESSMENT, INNOVATION, PERSONALISED, FUTURE

RetiCare IVS – Setting the sight on new treatments for retinal diseases

RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.

The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.

Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.

The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.

RiboStruct is developing the first generic treatment for genetic diseases.

RiboStruct leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the crystallographic study of the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the human ribosome for the treatment of monogenic genetic diseases when they are caused by nonsense mutations (10-15% of cases).
Distinctively from gene therapies, where a specific program is needed for each disease, RiboStruct develops a pharmacological "protein repair therapy" approach, with the goal to cure multiple diseases with the same molecule by acting on a common mechanism. More than 7000 genetic diseases have been described so far, affecting altogether 300 million people worlwide.

Genetic diseases

Nonsense mutations

Premature stop codons

Readthrough

Human ribosome

Structure-based drug design

Dr Renaud Jean-Paul, President & CEO-CSO

RiboStruct is trying to achieve a first round of funding.

Aminoglycosides are known to help the ribosome overcome premature stop codons to restore the synthesis of full-length proteins but their high toxicity prevents their use on the long term as needed for the treatment of monogenic diseases caused by nonsense mutations.

RiboStruct is developing non-aminoglycoside readthrough compounds using a fragment- and structure-based drug design approach relying on an exclusive know-how on the crystallographic structure determination of the whole eukaryotic ribosome in complex with ligands and on the strong biophysical capabilities of its strategic partner NovAliX (http://www.novalix-pharma.com/).

cancer, immunotherapy, vaccine, telomerase